1 / 29

Five-Year Follow-Up After Clinical Islet Transplantation Ryan et al, Diabetes 54:2060-2069, 2005.

Prolonged Diabetes Reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates Hering et al, Nature Medicine 12:301-303, 2006. Reversal Diabetes > 100 days Porcine islet transplants into streptozotocin diabetic cynomolgus macaques

raoul
Download Presentation

Five-Year Follow-Up After Clinical Islet Transplantation Ryan et al, Diabetes 54:2060-2069, 2005.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Prolonged Diabetes Reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates Hering et al, Nature Medicine 12:301-303, 2006 • Reversal Diabetes > 100 days Porcine islet transplants into streptozotocin diabetic cynomolgus macaques • Required Rx with toxic regimen including anti-CD154, leflunomide, basiliximab, FTY720 and everolimus • No Gal-specific antibody mediated hyperacute rejection

  2. Five-Year Follow-Up After Clinical Islet TransplantationRyan et al, Diabetes 54:2060-2069, 2005. Percent derived from life Table Months of Follow-up

  3. Issues in Islet Graft Transplantation • Allograft immunity • Xenograft immunity • Autoimmunity

  4. Transplant Immunity Autoimmunity Islets

  5. >13 ,000 World Experience in Organ / Tissue Transplantation Kidney >500,000 Heart >50,000 Pancreas Islet <500 0 200000 100000 300000 400000 500000 600000 Number of transplants

  6. Autografts:islets obtained from the recipient to prevent pancreatectomy-induced diabetes Allografts: islets obtained from an unrelated donor to prevent pancreatectomy-induced diabetes Allografts + IDDM: islets obtained from an unrelated donor after or at the same time as kidney transplantation Clinical Experience in Islet Transplantation

  7. Islet Transplantation Registry 1990 - 1997 100 90 80 Autografts (n=50, 50%) 70 60 % Insulin-Independence 50 40 Allografts (n=15, 40%) 30 20 Allografts + IDDM (n=200, 8%) 10 0 10 1 7 8 2 3 5 9 11 12 0 4 6 Months post-transplantation

  8. Possible Reasons for Islet Graft Failure Insufficient islet mass Poor quality of islets Failure to engraft Toxicity of anti- rejection drugs Islets Insulin resistance Disease recurrence Allograft rejection

  9. `Edmonton’ Protocol University of Alberta, Edmonton, Alberta J. Shapiro, M.D. R. Rajotte, Ph.D. • Islet-alone transplantation trial • Type 1 diabetic patients received two transplants of large numbers of high quality islets. • Standard immunosuppressive therapy was • replaced with a steroid-free protocol: Daclizumab (DZB) (anti-IL2 receptor antibody) Daily doses of sirolimus and low-dose tacrolimus

  10. Eligibility Criteria • 18-55 years of age, have had IDDM for >5 years • Hypoglycemia unawareness requiring medical assistance • Uncontrolled blood sugars despite intensive insulin therapy (“ brittle diabetes”). • Evidence of early diabetic nephropathy or other secondary complications

  11. Exclusion Criteria • cardiac disease or psychiatric illness • active alcohol or substance abuse • previous transplant • a history of malignancy or abnormal liver function • an active infection (HIV, Hepatitis B or C, TB)

  12. `Edmonton Protocol’ Results • 13 consecutive cases of insulin-independence with a duration of (longest > 2.5 years) • normalization of HbA1C values (mean of 5.7% at 3 and 6 months post-transplantation) • no episodes of hypoglycemia • no episodes of acute rejection and minimal toxicity from anti-rejection drug therapy

  13. Pre-transplant 600 500 400 Blood glucose (mg/dl) 300 200 100 0 Shapiro et al. N Engl J Med 2000; 343:230-238 600 500 Post-transplant 400 Blood glucose (mg/dl) 300 200 100 0 2 4 6 12 2 4 8 10 12 6 8 10 a.m. p.m. Time of day

  14. Islet Transplantation: The NIH ExperienceDiabetes Care 2003: 26:3288-95 • Major Procedure ComplicationsPartial portal vein thrombosisIntra-abdominal hemorrhage • Immunosupression ComplicationsKidney ToxicitySirolimun-induced Pneumonitis • Three Patients Discontinued Immunotherapy ½ Patients insulin-independent at one year Decreased Hypoglycemia and less severe Hypoglycemia

  15. Percent 4 Year Survival with Pancreas Transplant Ventrom et al JAMA 2003; 290: 2817-2823

  16. Future Directions • Reduce requirement to single pancreas / recipient • Interventions to reduce peri-transplant inflammation • Progress towards ‘tolerizing’ strategies

  17. Alternative sources of tissue • insulin-producing cell lines • stem cells • xenografts (other species)

  18. Experimental Islet Transplantation C57Bl/6 mouse (H-2b) Remove pancreas Streptozotocin-induced diabetic BALB/c mouse (H-2d) Isolate islets Transplant islets under kidney capsule

  19. Key Components to Islet Allograft Cellular Rejection • Donor-derived APCs • Donor MHC class I expression • Host CD8 T cells • Variable requirement for CD4 T cell help

  20. Key Components to Islet Xenograft Cellular Rejection • Host-derived APCs • Host MHC class II expression • Host CD4 T cells

  21. Conclusion / Hypothesis • Allograft Rejection --> Predominant CD8- dependent ‘direct’ recognition • Xenograft Rejection and Autoimmune pathogenesis --> Predominant CD4- dependent ‘indirect’ recognition

  22. Anti-LFA-1 Therapy Facilitates Long-Term Islet Allograft Acceptance(C57Bl/6 --> BALB/c) 100 80 60 % Grafts Functioning Anti-LFA-1 (n = 20) 40 Control Ig (n = 10) 20 0 0 20 40 60 80 100 Days PostTransplantation

  23. Failure of Anti-LFA-1 to Prevent Disease Recurrence(NOD --> NOD) 100 80 Untreated (n = 10) 60 % Grafts Functioning Anti-LFA-1 (n = 8) 40 Young SZ-NOD (n = 3) 20 0 0 20 40 60 80 100 Days Post Transplantation

  24. Anti-CD4 but not anti-CD8 therapy prevents acute disease recurrence in NOD mice 1 0 0 8 0 Untreated (n=8) Anti-CD8 (116-13.1; n=10) 6 0 % Grafts Functioning Anti-CD4 (GK1.5; n=9) 4 0 0 2 0 0 8 0 2 0 4 0 6 0 1 0 0 Days Post-transplantation

  25. C (1) T C APC T (C) (C) (2) C CoS C (1) No b cell T C Response (C) C The Stimulator Cell Model

  26. DIRECT A (1) DONOR T T A APC (A) (A) (2) A Shed Graft Antigens INDIRECT (X) x B (1) T HOST T x B (B.X) (B.X) APC (2) B x

  27. CD4 T Cell B Cell Delayed-Type CD8 T Cell Help Help Hypersensitivity GRAFT

  28. TOLERANCE

More Related